MicroRNAs in pathogenesis of breast cancer: Implications in diagnosis and treatment

World Journal of Clinical Oncology

Volumn 5, Issue 2, 2014, Pages 48-60

  Shah, Nirav R ^a   Chen, Hexin ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Breast cancer; Cancer stem cells; Diagnostic markers; Drug resistance; MicroRNAs

Indexed keywords

EID: 84907857371     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i2.48     Document Type: Article

References (119)

1. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-7070 [PMID: 16103053 DOI: 10.1158/0008-5472.CAN-05-1783]
2. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavaré S, Caldas C, Miska EA. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007; 8: R214 [PMID: 17922911 DOI: 10.1186/gb-2007-8-10-r214]
3. Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, Griffiths-Jones S, Marshall M, Matzke M, Ruvkun G, Tuschl T. A uniform system for microRNA annotation. RNA 2003; 9: 277-279 [PMID: 12592000]
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297 [PMID: 14744438]
5. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rådmark O, Kim S, Kim VN. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425: 415-419 [PMID: 14508493 DOI: 10.1038/nature01957]
6. Cookson VJ, Bentley MA, Hogan BV, Horgan K, Hayward BE, Hazelwood LD, Hughes TA. Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell Oncol (Dordr) 2012; 35: 301-308 [PMID: 22821209 DOI: 10.1007/s13402-012-0089-1]
7. Corsini LR, Bronte G, Terrasi M, Amodeo V, Fanale D, Fiorentino E, Cicero G, Bazan V, Russo A. The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets 2012; 16 Suppl 2: S103-S109 [PMID: 22443195 DOI: 10.1517/14728222.2011.650 632]
8. Herranz M, Ruibal A. Optical imaging in breast cancer diagnosis: the next evolution. J Oncol 2012; 2012: 863747 [PMID: 23304141 DOI: 10.1155/2012/863747]
9. Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, Arlt D, Rath M, Sohn C, Benner A, Junkermann H, Schneeweiss A, Burwinkel B. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 2013; 132: 1602-1612 [PMID: 22927033 DOI: 10.1002/ijc. 27799]
10. Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, Brown M, Hafner M, Reyal F, van Kouwenhove M, Kreike B, Sie D, Hovestadt V, Wessels LF, van de Vijver MJ, Tuschl T. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res 2011; 71: 4443-4453 [PMID: 21586611 DOI: 10.1158/0008-5472. CAN-11-0608]
11. Tang J, Ahmad A, Sarkar FH. The Role of MicroRNAs in Breast Cancer Migration, Invasion and Metastasis. Int J Mol Sci 2012; 13: 13414-13437 [PMID: 23202960 DOI: 10.3390/ijms131013414]
12. Zhang CM, Zhao J, Deng HY. MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci 2013; 20: 79 [PMID: 24152184 DOI: 10.1186/1423-0127-20-79]
13. Markou A, Yousef GM, Stathopoulos E, Georgoulias V, Lianidou E. Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long followup. Clin Chem 2014; 60: 197-205 [PMID: 24132943 DOI: 10.1373/clinchem.2013.210542]
14. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Puré E, Agami R. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008; 10: 202-210 [PMID: 18193036 DOI: 10.1038/ncb1681]
15. Plummer PN, Freeman R, Taft RJ, Vider J, Sax M, Umer BA, Gao D, Johns C, Mattick JS, Wilton SD, Ferro V, McMillan NA, Swarbrick A, Mittal V, Mellick AS. MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells. Cancer Res 2013; 73: 341-352 [PMID: 22836757 DOI: 10.1158/0008-5472.CAN-12-0271]
16. Li Q, Zhu F, Chen P. miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer. Biochem Biophys Res Commun 2012; 424: 28-33 [PMID: 22705304 DOI: 10.1016/j.bbrc.2012.06.028]
17. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-688 [PMID: 17898713 DOI: 10.1038/nature06174]
18. Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2012; 481: 190-194 [PMID: 22170610 DOI: 10.1038/nature10661]
19. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 2008; 28: 6773-6784 [PMID: 18794355 DOI: 10.1128/MCB.00941-08]
20. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, Cheng JQ. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010; 285: 17869-17879 [PMID: 20371610 DOI: 10.1074/jbc.M110.101055]
21. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF, Wang ED. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010; 70: 3119-3127 [PMID: 20354188 DOI: 10.1158/0008-5472.CAN-09-4250]
22. Qi L, Bart J, Tan LP, Platteel I, Sluis Tv, Huitema S, Harms G, Fu L, Hollema H, Berg Av. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer 2009; 9: 163 [PMID: 19473551 DOI: 10.1186/1471-2407-9-163]
23. Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat 2009; 117: 131-140 [PMID: 18932017 DOI: 10.1007/s10549-008-0219-7]
24. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14: 2348-2360 [PMID: 18812439 DOI: 10.1261/rna.1034808]
25. Ru P, Steele R, Hsueh EC, Ray RB. Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. Genes Cancer 2011; 2: 720-727 [PMID: 22207897 DOI: 10.1177/1947601911425832]
26. Yang K, Handorean AM, Iczkowski KA. MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro. Int J Clin Exp Pathol 2009; 2: 361-369 [PMID: 19158933]
27. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-256 [PMID: 20173740 DOI: 10.1038/ncb2024]
28. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008; 283: 29897-29903 [PMID: 18708351 DOI: 10.1074/jbc.M804612200]
29. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, Newman RJ, Yue P, Bourgon R, Modrusan Z, Stern HM, Warming S, de Sauvage FJ, Amler L, Yeh RF, Dornan D. miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelialto-mesenchymal transition in breast cancer. Sci Signal 2011; 4: pt5 [PMID: 21868360 DOI: 10.1126/scisignal.2002258]
30. Mitra A, Rostas JW, Dyess DL, Shevde LA, Samant RS. Micro-RNA-632 downregulates DNAJB6 in breast cancer. Lab Invest 2012; 92: 1310-1317 [PMID: 22710984 DOI: 10.1038/labinvest. 2012.87]
31. Harquail J, Benzina S, Robichaud GA. MicroRNAs and breast cancer malignancy: an overview of miRNA-regulated cancer processes leading to metastasis. Cancer Biomark 2012; 11: 269-280 [PMID: 23248185 DOI: 10.3233/CBM-120291]
32. Ali AS, Ali S, Ahmad A, Bao B, Philip PA, Sarkar FH. Expression of microRNAs: potential molecular link between obesity, diabetes and cancer. Obes Rev 2011; 12: 1050-1062 [PMID: 21767342 DOI: 10.1111/j.1467-789X.2011.00906.x]
33. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131: 1109-1123 [PMID: 18083101 DOI: 10.1016/j.cell.2007.10.054]
34. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, Wells W, Kauppinen S, Cole CN. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007; 67: 11612-11620 [PMID: 18089790 DOI: 10.1158/0008-5472.CAN-07-5019]
35. Cunningham HD, Shannon LA, Calloway PA, Fassold BC, Dunwiddie I, Vielhauer G, Zhang M, Vines CM. Expression of the C-C chemokine receptor 7 mediates metastasis of breast cancer to the lymph nodes in mice. Transl Oncol 2010; 3: 354-361 [PMID: 21151474]
36. Kim SJ, Shin JY, Lee KD, Bae YK, Sung KW, Nam SJ, Chun KH. MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res 2012; 14: R14 [PMID: 22251626 DOI: 10.1186/bcr3098]
37. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS, Huang WL, Zeng YX, Shao JY. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res 2011; 71: 3552-3562 [PMID: 21444677 DOI: 10.1158/0008-5472.CAN-10-2435]
38. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282: 1479-1486 [PMID: 17110380 DOI: 10.1074/jbc.M609383200]
39. Feliciano A, Castellvi J, Artero-Castro A, Leal JA, Romagosa C, Hernández-Losa J, Peg V, Fabra A, Vidal F, Kondoh H, Ramón Y Cajal S, Lleonart ME. miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9. PLoS One 2013; 8: e76247 [PMID: 24098452 DOI: 10.1371/journal.pone.0076247]
40. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RA, Lao K, Clarke MF. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603 [PMID: 19665978 DOI: 10.1016/j. cell.2009.07.011]
41. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massagué J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147-152 [PMID: 18185580 DOI: 10.1038/nature06487]
42. Png KJ, Yoshida M, Zhang XH, Shu W, Lee H, Rimner A, Chan TA, Comen E, Andrade VP, Kim SW, King TA, Hudis CA, Norton L, Hicks J, Massagué J, Tavazoie SF. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev 2011; 25: 226-231 [PMID: 21289068 DOI: 10.1101/gad.1974211]
43. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res 2010; 70: 5147-5154 [PMID: 20530680 DOI: 10.1158/0008-5472.CAN-10-0410]
44. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009; 137: 1032-1046 [PMID: 19524507 DOI: 10.1016/j.cell.2009.03.047]
45. Cha ST, Chen PS, Johansson G, Chu CY, Wang MY, Jeng YM, Yu SL, Chen JS, Chang KJ, Jee SH, Tan CT, Lin MT, Kuo ML. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res 2010; 70: 2675-2685 [PMID: 20233879 DOI: 10.1158/0008-5472. CAN-09-2448]
46. Abdelmohsen K, Kim MM, Srikantan S, Mercken EM, Brennan SE, Wilson GM, Cabo Rd, Gorospe M. miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle 2010; 9: 1354-1359 [PMID: 20305372]
47. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21: 283-296 [PMID: 22439924 DOI: 10.1016/j.ccr.2012.03.003]
48. Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2013; 2: 3 [PMID: 23369605 DOI: 10.1186/2001-1326-2-3]
49. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988 [PMID: 12629218 DOI: 10.1073/pnas.0530291100]
50. Schwarzenbacher D, Balic M, Pichler M. The role of microRNAs in breast cancer stem cells. Int J Mol Sci 2013; 14: 14712-14723 [PMID: 23860207 DOI: 10.3390/ijms140714712]
51. Sakurai M, Miki Y, Masuda M, Hata S, Shibahara Y, Hirakawa H, Suzuki T, Sasano H. LIN28: a regulator of tumorsuppressing activity of let-7 microRNA in human breast cancer. J Steroid Biochem Mol Biol 2012; 131: 101-106 [PMID: 22081076 DOI: 10.1016/j.jsbmb.2011.10.007]
52. Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduc-tion maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010; 29: 4194-4204 [PMID: 20498642 DOI: 10.1038/onc.2010.167]
53. Ouzounova M, Vuong T, Ancey PB, Ferrand M, Durand G, Le-Calvez Kelm F, Croce C, Matar C, Herceg Z, Hernandez-Vargas H. MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells. BMC Genomics 2013; 14: 139 [PMID: 23445407 DOI: 10.1186/1471-2164-14-139]
54. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 2010; 39: 761-772 [PMID: 20832727 DOI: 10.1016/j. molcel. 2010.08.013]
55. Lim YY, Wright JA, Attema JL, Gregory PA, Bert AG, Smith E, Thomas D, Lopez AF, Drew PA, Khew-Goodall Y, Goodall GJ. Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. J Cell Sci 2013; 126: 2256-2266 [PMID: 23525011 DOI: 10.1242/jcs.122275]
56. Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H, Gong C, Chen J, Su F, Zhang Y, Song E. Reduced miR-128 in breast tumorinitiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 2011; 17: 7105-7115 [PMID: 21953503 DOI: 10.1158/1078-0432.CCR-11-0071]
57. Qian P, Banerjee A, Wu ZS, Zhang X, Wang H, Pandey V, Zhang WJ, Lv XF, Tan S, Lobie PE, Zhu T. Loss of SNAIL regulated miR-128-2 on chromosome 3p22.3 targets multiple stem cell factors to promote transformation of mammary epithelial cells. Cancer Res 2012; 72: 6036-6050 [PMID: 23019226 DOI: 10.1158/0008-5472.CAN-12-1507]
58. Liu S, Patel SH, Ginestier C, Ibarra I, Martin-Trevino R, Bai S, McDermott SP, Shang L, Ke J, Ou SJ, Heath A, Zhang KJ, Korkaya H, Clouthier SG, Charafe-Jauffret E, Birnbaum D, Hannon GJ, Wicha MS. MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet 2012; 8: e1002751 [PMID: 22685420 DOI: 10.1371/journal.pgen.1002751]
59. Yu F, Jiao Y, Zhu Y, Wang Y, Zhu J, Cui X, Liu Y, He Y, Park EY, Zhang H, Lv X, Ma K, Su F, Park JH, Song E. MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells. J Biol Chem 2012; 287: 465-473 [PMID: 22074923 DOI: 10.1074/jbc.M111.280768]
60. Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, Chen H, Lu X. Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res 2010; 70: 7176-7186 [PMID: 20668064 DOI: 10.1158/0008-5472. CAN-10-0697]
61. Hwang-Verslues WW, Chang PH, Wei PC, Yang CY, Huang CK, Kuo WH, Shew JY, Chang KJ, Lee EY, Lee WH. miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene 2011; 30: 2463-2474 [PMID: 21258409 DOI: 10.1038/onc.2010.618]
62. Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L. Intracellular and extracellular microRNAs in breast cancer. Clin Chem 2011; 57: 18-32 [PMID: 21059829 DOI: 10.1373/clin chem.2010.150730]
63. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7: 2152-2159 [PMID: 18645025 DOI: 10.1158/1535-7163. MCT-08-0021]
64. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 2010; 127: 1785-1794 [PMID: 20099276 DOI: 10.1002/ijc.25191]
65. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008; 283: 31079-31086 [PMID: 18790736 DOI: 10.1074/jbc.M806041200]
66. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O, Riker AI, Tan M. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010; 285: 21496-21507 [PMID: 20460378 DOI: 10.1074/jbc.M109.083337]
67. Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 2006; 580: 998-1009 [PMID: 16405967 DOI: 10.1016/j.febslet.2005.12.060]
68. Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 2010; 31: 2049-2057 [PMID: 20876285 DOI: 10.1093/carcin/bgq192]
69. Kato M, Paranjape T, Müller RU, Nallur S, Gillespie E, Keane K, Esquela-Kerscher A, Weidhaas JB, Slack FJ. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene 2009; 28: 2419-2424 [PMID: 19421141 DOI: 10.1038/onc.2009.106]
70. Li L, Yuan L, Luo J, Gao J, Guo J, Xie X. MiR-34a inhibits proliferation and migration of breast cancer through downregulation of Bcl-2 and SIRT1. Clin Exp Med 2013; 13: 109-117 [PMID: 22623155 DOI: 10.1007/s10238-012-0186-5]
71. Reardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bisaceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999; 59: 3968-3971 [PMID: 10463593]
72. Xin F, Li M, Balch C, Thomson M, Fan M, Liu Y, Hammond SM, Kim S, Nephew KP. Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics 2009; 25: 430-434 [PMID: 19091772 DOI: 10.1093/bioinformatics/btn646]
73. Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M, García-Foncillas J. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006; 5: 29 [PMID: 16854228 DOI: 10.1186/1476-4598-5-29]
74. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, Nuovo GJ, Fishel R, Croce CM. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA 2010; 107: 21098-21103 [PMID: 21078976 DOI: 10.1073/pnas.1015541107]
75. Thangaraju M, Kaufmann SH, Couch FJ. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem 2000; 275: 33487-33496 [PMID: 10938285 DOI: 10.1074/jbc.M005824200]
76. Yao E, Ventura A. A new role for miR-182 in DNA repair. Mol Cell 2011; 41: 135-137 [PMID: 21255724 DOI: 10.1016/j.molcel.2011.01.005]
77. Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, Lidereau R, Mikaélian I, Mazoyer S. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med 2011; 3: 279-290 [PMID: 21472990 DOI: 10.1002/emmm.201100136]
78. Liang Z, Ahn J, Guo D, Votaw JR, Shim H. MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharm Res 2013; 30: 1008-1016 [PMID: 23184229 DOI: 10.1007/s11095-012-0936-9]
79. Jameel JK, Rao VS, Cawkwell L, Drew PJ. Radioresistance in carcinoma of the breast. Breast 2004; 13: 452-460 [PMID: 15563851 DOI: 10.1016/j.breast.2004.08.004]
80. Piva R, Spandidos DA, Gambari R. From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review). Int J Oncol 2013; 43: 985-994 [PMID: 23939688 DOI: 10.3892/ijo.2013.2059]
81. Ng EK, Li R, Shin VY, Siu JM, Ma ES, Kwong A. MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells. Tumour Biol 2014; 35: 2591-2598 [PMID: 24218337 DOI: 10.1007/s1327 7-013-1341-7]
82. Duursma AM, Kedde M, Schrier M, le Sage C, Agami R. miR-148 targets human DNMT3b protein coding region. RNA 2008; 14: 872-877 [PMID: 18367714 DOI: 10.1261/rna. 972008]
83. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104: 15805-15810 [PMID: 17890317 DOI: 10.1073/pnas. 0707628104]
84. Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove R, Xu R, Huang W. miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology 2010; 52: 2148-2157 [PMID: 20979124 DOI: 10.1002/hep. 23915]
85. Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008; 105: 13556-13561 [PMID: 18768788 DOI: 10.1073/pnas.0803055105]
86. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]
87. Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011; 30: 1082-1097 [PMID: 21057537 DOI: 10.1038/onc.2010.487]
88. Sachdeva M, Wu H, Ru P, Hwang L, Trieu V, Mo YY. MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene 2011; 30: 822-831 [PMID: 20956939 DOI: 10.1038/onc.2010.463]
89. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007; 12: 20-37 [PMID: 17227898 DOI: 10.1634/theoncologist.12-1-20]
90. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 2008; 54: 1696-1704 [PMID: 18719201 DOI: 10.1373/clinchem. 2007.101741]
91. Ben-Hamo R, Efroni S. MicroRNA-gene association as a prognostic biomarker in cancer exposes disease mechanisms. PLoS Comput Biol 2013; 9: e1003351 [PMID: 24278004 DOI: 10.1371/journal.pcbi.1003351]
92. Singh R, Mo YY. Role of microRNAs in breast cancer. Cancer Biol Ther 2013; 14: 201-212 [PMID: 23291983 DOI: 10.4161/cbt.23296]
93. Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, Pang R, Chua D, Chu KM, Law WL, Law SY, Poon RT, Kwong A. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One 2013; 8: e53141 [PMID: 23301032 DOI: 10.1371/journal.pone.0053141]
94. Godfrey AC, Xu Z, Weinberg CR, Getts RC, Wade PA, Deroo LA, Sandler DP, Taylor JA. Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Breast Cancer Res 2013; 15: R42 [PMID: 23705859 DOI: 10.1186/bcr3428]
95. Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, Li J. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One 2012; 7: e47003 [PMID: 23071695 DOI: 10.1371/journal.pone.0047003]
96. Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, Schott S, Heil J, Turchinovich A, Yang R, Benner A, Riethdorf S, Trumpp A, Sohn C, Pantel K, Schneeweiss A, Burwinkel B. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res 2012; 18: 5972-5982 [PMID: 22952344 DOI: 10.1158/1078-0432. CCR-12-1407]
97. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-2803 [PMID: 17072344 DOI: 10.1038/sj.onc.1210083]
98. Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med 2009; 13: 39-53 [PMID: 19175699 DOI: 10.1111/j.1582-4934.2008.00556.x]
99. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4: 721-726 [PMID: 17694064 DOI: 10.1038/nmeth1079]
100. Song SJ, Poliseno L, Song MS, Ala U, Webster K, Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, Richardson AL, Pandolfi PP. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 2013; 154: 311-324 [PMID: 23830207 DOI: 10.1016/j.cell.2013.06.026]
101. Lu Y, Xiao J, Lin H, Bai Y, Luo X, Wang Z, Yang B. A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res 2009; 37: e24 [PMID: 19136465 DOI: 10.1093/nar/gkn1053]
102. Gumireddy K, Young DD, Xiong X, Hogenesch JB, Huang Q, Deiters A. Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl 2008; 47: 7482-7484 [PMID: 18712719 DOI: 10.1002/anie.200801555]
103. Watashi K, Yeung ML, Starost MF, Hosmane RS, Jeang KT. Identification of small molecules that suppress microRNA function and reverse tumorigenesis. J Biol Chem 2010; 285: 24707-24716 [PMID: 20529860 DOI: 10.1074/jbc.M109.062976]
104. Brognara E, Fabbri E, Aimi F, Manicardi A, Bianchi N, Finotti A, Breveglieri G, Borgatti M, Corradini R, Marchelli R, Gambari R. Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells. Int J Oncol 2012; 41: 2119-2127 [PMID: 22992757 DOI: 10.3892/ijo.2012.1632]
105. Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, Fu J, Zeng MS, Yun JP, Wu QL, Zeng YX, Shao JY. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res 2011; 13: R2 [PMID: 21219636 DOI: 10.1186/bcr2803]
106. Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, Uhlmann S, Zhang JD, Wiemann S, Sahin Ö. MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol Cell Biol 2012; 32: 633-651 [PMID: 22144583 DOI: 10.1128/MCB.06212-11]
107. Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 2013; 93: 98-104 [PMID: 23212103 DOI: 10.1038/clpt.2012.192]
108. Gabriely G, Teplyuk NM, Krichevsky AM. Context effect: microRNA-10b in cancer cell proliferation, spread and death. Autophagy 2011; 7: 1384-1386 [PMID: 21795860 DOI: 10.4161/auto.7.11.17371]
109. Huang GL, Zhang XH, Guo GL, Huang KT, Yang KY, Shen X, You J, Hu XQ. Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep 2009; 21: 673-679 [PMID: 19212625]
110. Ward A, Balwierz A, Zhang JD, Küblbeck M, Pawitan Y, Hielscher T, Wiemann S, Sahin Ö. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 2013; 32: 1173-1182 [PMID: 22508479 DOI: 10.1038/onc.2012.128]
111. de Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R, Malekpour F, Volinia S, Croce CM, Najmabadi H, Diederichs S, Sahin O, Mayer D, Lyko F, Hoheisel JD, Riazalhosseini Y. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 2010; 70: 9175-9184 [PMID: 20978187 DOI: 10.1158/0008-5472.CAN-10-1318]
112. Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P, Wood CG, Wu X. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 2010; 29: 5724-5728 [PMID: 20676129 DOI: 10.1038/onc.2010.305]
113. Khew-Goodall Y, Goodall GJ. Myc-modulated miR-9 makes more metastases. Nat Cell Biol 2010; 12: 209-211 [PMID: 20173743 DOI: 10.1038/ncb0310-209]
114. Bueno MJ, Malumbres M. MicroRNAs and the cell cycle. Biochim Biophys Acta 2011; 1812: 592-601 [PMID: 21315819 DOI: 10.1016/j.bbadis.2011.02.002]
115. Guo Y, Liu Y, Li Z, Wang D, Du Y, Chen J, Jin Z. EUS-guided implantation of radioactive iodine-125 seeds in retroperitoneal metastatic adenocarcinoma. Endoscopy 2009; 41 Suppl 2: E301 [PMID: 19911342 DOI: 10.1055/s-0029-1214499]
116. Guo L, Chen C, Shi M, Wang F, Chen X, Diao D, Hu M, Yu M, Qian L, Guo N. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene 2013; 32: 5272-5282 [PMID: 23318420 DOI: 10.1038/onc.2012.573]
117. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907 [PMID: 18381893 DOI: 10.1101/gad.1640608]
118. Zhou J, Tian Y, Li J, Lu B, Sun M, Zou Y, Kong R, Luo Y, Shi Y, Wang K, Ji G. miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun 2013; 433: 207-212 [PMID: 23466356 DOI: 10.1016/j.bbrc.2013.02.084]
119. Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, Jones FE. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer 2010; 9: 317 [PMID: 21172025 DOI: 10.1186/1476-4598-9-317]